Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/cmmm/volume-2021/5534823/figures/5534823.fig.002a.svgz" name="5534823.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Overall risk of bias</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/cmmm/volume-2021/5534823/figures/5534823.fig.002b.svgz" name="5534823.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Risk of bias for each RCT</td></tr></table>

<div>Cochrane’s bias risk assessment.</div>

Computational and Mathematical Methods in Medicine

fig2

Figure 2

Figure 2: Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis 